When hantavirus struck passengers aboard a cruise ship and threatened to spread, there was nothing in medicine's arsenal to treat the sick or shield the vulnerable. The virus—a deadly rodent-borne pathogen known to science for decades—had no approved drugs, no vaccines, and no clear path forward despite decades of research.
That gap in protection matters urgently. Unlike novel pathogens that catch the world by surprise, hantavirus has been well-documented for years, yet governments, global health organizations, and pharmaceutical companies have consistently declined sustained investment because infections remain rare and the virus spreads poorly between people. But rarity does not mean insignificance: in Chile, the Ministry of Health confirmed 15 deaths and 42 cases so far this year. Argentina has reported 32 deaths and 102 cases since June 2025. On the cruise ship itself, three of thirteen likely cases ended in death. In the United States, where tracking began in 1993, fully 35 percent of hantavirus cases have proven fatal.
The Andes virus, which sparked the cruise outbreak, has become the focus of intense research attention. It is the only hantavirus species capable of spreading from person to person, making it a particular public health concern. Other hantavirus species—like the Sin Nombre virus found in North America—typically spread when people inhale contaminated rodent droppings. "That is why it is a public health problem," explained María Inés Barría, a virologist at the Universidad San Sebastián in Santiago, Chile.
Now, researchers across three countries are pursuing a breakthrough. In Argentina, a team led by Dr. Fernando Tortosa of the National University of Río Negro in Patagonia has published promising results in The Lancet Infectious Diseases showing that tocilizumab, a drug developed to treat rheumatoid arthritis, may help hantavirus patients survive the infection's most devastating phase. The drug works by blocking IL-6, a molecule that triggers the dangerous inflammatory response that causes lungs to fill with fluid and shut down.
In a compassionate-use study—where doctors administer experimental treatments to eligible patients outside formal trials—four of five patients who received tocilizumab alongside standard supportive care survived hantavirus pulmonary syndrome. The findings, published on Wednesday, represent the first documented use of tocilizumab for this virus and suggest a pathway toward reducing deaths from the infection's most severe form.
The research effort extends across Chile, Argentina, and the United States, with scientists working to develop not just treatments but also vaccines. Yet these teams face the same funding constraint that has plagued hantavirus research for years: without the commercial incentive of a common disease or the political urgency of a novel outbreak, resources remain scarce.
Dr. Tortosa expressed measured hope tempered with urgency. "I hope this situation will help us continue our research and strengthen the collaboration between healthcare workers, the community, and the necessary resources," he said. The cruise ship outbreak and growing climate concerns—as warming temperatures are expected to increase contact between humans and rodents—may finally provide the momentum needed to sustain the work. For researchers like Barría who have long pursued answers to a neglected threat, the moment feels like it could tip the scales toward discovery.